CANBRIDGE PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.45 HKD | -1.10% |
|
+1.12% | -54.55% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 3,069 | 918.1 | 177.1 | 177.1 | - |
| Enterprise Value (EV) 2 | 2,376 | 610.3 | 386.5 | -332.8 | -101.7 |
| P/E ratio | -0.63 x | -1.88 x | -1.03 x | -0.71 x | -0.6 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 98.5 x | 11.6 x | 3.71 x | 1.36 x | 0.65 x |
| EV / Revenue | 76.2 x | 7.73 x | 3.76 x | -2.56 x | -0.37 x |
| EV / EBITDA | -3.72 x | -1.4 x | -1.09 x | 2 x | 0.47 x |
| EV / FCF | -4,011,666 x | - | - | - | - |
| FCF Yield | -0% | - | - | - | - |
| Price to Book | 1.02 x | 2.95 x | -9.75 x | 0.22 x | 0.32 x |
| Nbr of stocks (in thousands) | 424,192 | 424,292 | 424,838 | 424,838 | - |
| Reference price 3 | 8.880 | 2.450 | 0.4500 | 0.4500 | 0.4500 |
| Announcement Date | 22-03-22 | 23-03-30 | 24-03-28 | - | - |
1HKD in Million2CNY in Million3HKD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 31.16 | 78.97 | 102.9 | 130 | 273.8 |
| EBITDA 1 | - | -639.4 | -436 | -353.8 | -166.1 | -214.9 |
| EBIT 1 | - | -655.1 | -476.6 | -369.9 | -192.2 | -237.7 |
| Operating Margin | - | -2,102.46% | -603.52% | -359.57% | -147.83% | -86.83% |
| Earnings before Tax (EBT) 1 | - | -1,077 | -483.5 | -378.8 | -250.5 | -293.3 |
| Net income 1 | -846 | -1,077 | -483.5 | -378.8 | -250.5 | -293.3 |
| Net margin | - | -3,456.26% | -612.21% | -368.26% | -192.67% | -107.13% |
| EPS 2 | -15.11 | -14.04 | -1.302 | -0.9638 | -0.6380 | -0.7515 |
| Free Cash Flow | - | -592.2 | - | - | - | - |
| FCF margin | - | -1,900.31% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 21-11-30 | 22-03-22 | 23-03-30 | 24-03-28 | - | - |
1CNY in Million2HKD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 4.44 | - | - |
| Net Cash position 1 | - | 694 | 308 | 230 | 510 | 279 |
| Leverage (Debt/EBITDA) | - | - | - | -0.0125 x | - | - |
| Free Cash Flow | - | -592 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -155% | -96.5% | -282% | -54.4% | -38.7% |
| ROA (Net income/ Total Assets) | - | -146% | - | - | - | - |
| Assets 1 | - | 739.4 | - | - | - | - |
| Book Value Per Share 2 | - | 8.710 | 0.8300 | -0.1000 | 2.080 | 1.410 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | 8.5 | - | - | - | - |
| Capex / Sales | - | 27.28% | - | - | - | - |
| Announcement Date | 21-11-30 | 22-03-22 | 23-03-30 | 24-03-28 | - | - |
1CNY in Million2HKD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.45
HKD
Average target price
7
HKD
Spread / Average Target
+1,455.56%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -54.55% | 24.47M | |
| +5.48% | 71.19B | |
| +12.55% | 9.3B | |
| -13.75% | 5.01B | |
| +42.38% | 4.47B | |
| +4.51% | 3.96B | |
| +21.10% | 2.44B | |
| -19.05% | 2.41B | |
| -28.72% | 2.23B | |
| +11.13% | 2.02B |
- Stock Market
- Equities
- 1228 Stock
- Financials CANbridge Pharmaceuticals Inc.
